Stay updated on Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.

Latest updates to the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page revision entry was updated from v3.4.2 to v3.4.3. The change adds Revision: v3.4.3 and removes Revision: v3.4.2.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe page update adds a Gastric cancer tag and a new link to the Genetic and Rare Diseases Information Center in the Resources section, and it updates the revision from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedFooter now displays Revision: v3.4.1, replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check53 days agoChange DetectedIntroduced a glossary toggle and added QC-related metadata (Last Update Submitted that Met QC Criteria and Last Update Posted) with revision updated to v3.4.0. Removed the previous QC label (Last Update Submitted that met QC Criteria), the estimated Last Update Posted label, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 was published, replacing the previous v3.3.3. No visible changes to the study details or page layout are indicated by the screenshot.SummaryDifference0.0%

- Check83 days agoChange DetectedNew location sections were added for California, Illinois, Massachusetts, New York, and Nouvelle-Aquitaine and old location sections were removed; the revision updated from v3.3.2 to v3.3.3.SummaryDifference0.4%

Stay in the know with updates to Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Zolbetuximab in CLDN18.2+ Gastric Cancer Clinical Trial page.